TOCRIS
a bio-techne brand

Print Date: Jan 15th 2016

Certificate of Analysis

www.tocris.com

Product Name: **PG 01** **Catalog No.: 3943** **Batch No.: 1**

CAS Number: 853138-65-5

IUPAC Name: *N*-Methyl-*N*-[2-[[4-(1-Methylethyl)phenyl]amino]-2-1*H*-indole-3-acetamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{28}H_{29}N_3O_2 \cdot ¼H_2O$

Batch Molecular Weight: 444.05

Physical Appearance: Off-white solid

Solubility: DMSO to 100 mM
ethanol to 5 mM

Storage: Store at -20°C

Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 98.3% purity

^{1}H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	75.74	6.7	9.46
Found	75.89	6.59	9.37

bio-techne.com
info@bio-techne.com
techsupport@bio-techne.com

North America
Tel: (800) 343 7475

China
info.cn@bio-techne.com
Tel: +86 (21) 52380373

Europe Middle East Africa
Tel: +44 (0)1235 529449

Rest of World
www.tocris.com/distributors
Tel:+1 612 379 2956

Product Name: **PG 01** **Catalog No.: 3943** **Batch No.: 1**

CAS Number: 853138-65-5

IUPAC Name: *N*-Methyl-*N*-[2-[[4-(1-Methylethyl)phenyl]amino]-2-1*H*-indole-3-acetamide

Description:

Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. Corrects gating defects of CFTR mutants such as ΔF508 (K_a = 0.3 μM), E193K and G970R (K_d values are 0.22 μM and 0.45 μM respectively). Increases ΔF508-CFTR Cl^- currents in the presence of forskolin; displays no effect on Ca^{2+}-activated Cl^- current.

Physical and Chemical Properties:

Batch Molecular Formula: $C_{28}H_{29}N_3O_2.¼H_2O$

Batch Molecular Weight: 444.05

Physical Appearance: Off-white solid

Minimum Purity: >98%

Batch Molecular Structure:



Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 100 mM
ethanol to 5 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Pedemonte *et al* (2005) Phenylglycine and sulphonamide correctors of defective DF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol.Pharmacol. ***67*** 1797. PMID: 15722457.

Caputo *et al* (2009) Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. J.Pharmacol.Exp.Ther. ***330*** 783. PMID: 19491324.

Pedemonte *et al* (2010) Influence of cell background on pharmacological rescue of mutant CFTR. Am.J.Physiol.Cell Physiol ***298*** C866. PMID: 20053923.